Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Histol Histopathol ; 28(1): 127-32, 2013 01.
Artículo en Inglés | MEDLINE | ID: mdl-23233065

RESUMEN

Intrauterine growth restriction (IUGR) is the leading cause of fetal mortality and morbidity. As an etiology, each of placental findings, maternal factors and fetal factors has been reported to be associated with IUGR, although a comprehensive approach to examine all of these parameters as a cause of IUGR has not been reported. In the present study, therefore, we comprehensively examined the placental findings and maternal and fetal factors in the cases of IUGR (n=257, mean maternal age, 30 years; gestational weeks, 34 weeks) and normal growth pregnancies (n=258, mean maternal age, 30 years; gestational weeks, 33 weeks), and determined risk factors for IUGR. The prevalence of pregnancy hypertension (PHT) (19% vs. 8%, P<0.01), smoking habit (3% vs. 0.7%, P<0.05) and fetal anomaly (3.5% vs. 0.8%, P<0.05) were higher in IUGR cases than normal growth pregnancies. Pathologically, the prevalence of infarction (33% vs. 14%, P<0.05), fetal vessel thrombosis (22% vs. 6%, P<0.001) and chronic villitis (11% vs. 3%, P<0.001) were higher in IUGR cases than those in normal growth pregnancies. A multivariable regression analysis revealed that maternal factors (PHT), fetal factors (anomaly), and placental findings (infarction, fetal vessel thrombosis, and chronic villitis) are independently associated with increased risk of IUGR (all P<0.01).


Asunto(s)
Retardo del Crecimiento Fetal/etiología , Retardo del Crecimiento Fetal/patología , Placenta/patología , Pueblo Asiatico , Femenino , Retardo del Crecimiento Fetal/epidemiología , Feto/patología , Humanos , Embarazo , Complicaciones del Embarazo/epidemiología , Prevalencia , Factores de Riesgo
2.
J Thromb Haemost ; 9(1): 201-8, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21029360

RESUMEN

BACKGROUND: High plasma levels of C-reactive protein (CRP) constitute a powerful predictive marker of cardiovascular events. Several lines of evidence suggest that CRP has prothrombogenic effects. However, whether CRP directly participates in the pathogenesis of thrombosis in vivo has not been fully clarified. OBJECTIVE: To test whether human CRP (hCRP) affects arterial thrombus formation after balloon injury of smooth muscle cell (SMC)-rich or macrophage-rich neointima. METHODS: We compared the susceptibility of transgenic (Tg) rabbits expressing hCRP (46.21 ± 13.85 mg L(-1), n = 22) and non-Tg rabbits to arterial thrombus formation after balloon injury of SMC-rich or macrophage-rich neointima. RESULTS: Thrombus size on SMC-rich or macrophage-rich neointima was significantly increased, and was accompanied by an increase in fibrin content in hCRP-Tg rabbits, as compared with non-Tg rabbits. Thrombus size did not significantly differ between SMC-rich and macrophage-rich neointima in hCRP-Tg rabbits. Tissue factor (TF) mRNA expression and activity in these neointimal lesions were significantly increased in hCRP-Tg rabbits as compared with non-Tg rabbits. The degree of CRP deposition correlated with the elevated TF expression and thrombus size on injured neointima. In addition, hCRP isolated from hCRP-Tg rabbit plasma induced TF mRNA expression and activity in rabbit cultured vascular SMCs. CONCLUSIONS: These results suggest that elevated plasma hCRP levels promote thrombus formation on injured SMC-rich neointima by enhancing TF expression, but have no additive effects in macrophage-rich neointima.


Asunto(s)
Proteína C-Reactiva/metabolismo , Arteria Femoral/metabolismo , Músculo Liso Vascular/metabolismo , Miocitos del Músculo Liso/metabolismo , Trombosis/genética , Túnica Íntima/metabolismo , Lesiones del Sistema Vascular/metabolismo , Animales , Animales Modificados Genéticamente , Proteína C-Reactiva/genética , Cateterismo , Proliferación Celular , Células Cultivadas , Modelos Animales de Enfermedad , Arteria Femoral/lesiones , Arteria Femoral/patología , Humanos , Hiperlipidemias/genética , Hiperlipidemias/metabolismo , Macrófagos/metabolismo , Masculino , Músculo Liso Vascular/lesiones , Músculo Liso Vascular/patología , Miocitos del Músculo Liso/patología , ARN Mensajero/metabolismo , Conejos , Tromboplastina/genética , Trombosis/sangre , Trombosis/metabolismo , Trombosis/patología , Factores de Tiempo , Túnica Íntima/lesiones , Túnica Íntima/patología , Regulación hacia Arriba , Lesiones del Sistema Vascular/sangre , Lesiones del Sistema Vascular/genética , Lesiones del Sistema Vascular/patología
3.
Eur J Pharmacol ; 403(3): 189-94, 2000 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-10973618

RESUMEN

Adrenomedullin, a novel hypotensive peptide, has been reported to be produced in the lung as well as in the adrenal medulla. However, the effect of adrenomedullin on lung function is still poorly understood. In this study, we detected the expression of both adrenomedullin mRNA and putative adrenomedullin receptor mRNA in primary cultures of rat type II pneumocytes. Adrenomedullin increased the secretion of phosphatidylcholine, the predominant component of pulmonary surfactant, by type II pneumocytes. The increase was partly inhibited by pretreatment with the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP-(8-37). Furthermore, the increased phosphatidylcholine secretion was significantly inhibited by several protein kinase C inhibitors, such as sphingosine, 2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]3-(1H-indol-3-yl) maleimide (Gö6983), 3-[1-(3-amidinothio)-propyl-1H-indoyl-3-yl]3-(1-methyl-1H-++ +indoyl-3-yl ) maleimide methane sulfonate (Ro-31-8220), and staurosporine. Our results suggest that adrenomedullin can be considered a candidate autocrine modulator of surfactant secretion in type II pneumocytes.


Asunto(s)
Broncodilatadores/farmacología , Pulmón/metabolismo , Péptidos/farmacología , Fosfatidilcolinas/metabolismo , Adrenomedulina , Animales , Broncodilatadores/antagonistas & inhibidores , Péptido Relacionado con Gen de Calcitonina/farmacología , Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina , Membrana Celular/efectos de los fármacos , Membrana Celular/ultraestructura , Células Cultivadas , Pulmón/citología , Pulmón/efectos de los fármacos , Fragmentos de Péptidos/farmacología , Péptidos/antagonistas & inhibidores , ARN Mensajero/biosíntesis , Ratas , Receptores de Adrenomedulina , Receptores de Péptidos/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
4.
Nippon Ganka Gakkai Zasshi ; 97(8): 947-54, 1993 Aug.
Artículo en Japonés | MEDLINE | ID: mdl-8368183

RESUMEN

The prevalence of diabetic ocular complications and the correlation between diabetic retinopathy and systemic factors were examined in 2,300 cases (4,600 eyes) with non-insulin-dependent diabetes mellitus. The prevalence of cataract was 66.7%, of retinopathy 37.0%, of refractive and accommodative change 6.2%, of glaucoma 1.9% (rubeotic glaucoma was 1.0%), of rubeosis iridis 1.5%, of iridocyclitis 0.8%, of extraocular muscle palsy 0.2%, and of ischemic optic neuropathy 0.1%. Duration of diabetes mellitus, HbA1C value, methods of diabetic control, age, diabetic nephropathy, diabetic neuropathy, hypertension, systolic blood pressure, diastolic blood pressure, and arteriosclerosis obliterans were related with diabetic retinopathy. We suggest that the management of diabetic patients needs sufficient attention in the cases with oral administration of medication, insulin therapy, and diabetic nephropathy.


Asunto(s)
Catarata/epidemiología , Diabetes Mellitus Tipo 2/complicaciones , Retinopatía Diabética/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Nefropatías Diabéticas/epidemiología , Neuropatías Diabéticas/epidemiología , Femenino , Humanos , Hipertensión/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia
5.
Nihon Kyobu Shikkan Gakkai Zasshi ; 31(2): 267-70, 1993 Feb.
Artículo en Japonés | MEDLINE | ID: mdl-7685838

RESUMEN

We report a case of lung cancer producing CA19-9 and amylase. A 58-year-old woman was admitted with dry cough and right chest pain. Chest X-ray and CT showed a mass shadow in the right lung field and right pleural effusion. Histological examination of a lung specimen obtained by TBLB and cytological examination of pleural effusion showed adenocarcinoma. The diagnosis of lung adenocarcinoma was made. CA19-9 values in serum and pleural effusion were very high. Amylase value was high in pleural effusion, but that in serum was normal. The amylase isozyme pattern was salivary-type. No abnormality was detected on abdominal CT and ultrasonography. In spite of treatment of the pleural effusion, the patient's condition gradually deteriorated and she died of respiratory failure. Histological examination of lung specimens obtained at necropsy showed moderately differentiated papillary type adenocarcinoma. Immunohistochemically, the tumor cells stained positively for both CA19-9 and amylase. We conclude that the lung cancer produced both CA19-9 and amylase.


Asunto(s)
Adenocarcinoma Papilar/diagnóstico , Amilasas/análisis , Antígenos de Carbohidratos Asociados a Tumores/análisis , Biomarcadores de Tumor/análisis , Neoplasias Pulmonares/diagnóstico , Adenocarcinoma Papilar/metabolismo , Adenocarcinoma Papilar/patología , Amilasas/biosíntesis , Antígenos de Carbohidratos Asociados a Tumores/biosíntesis , Biomarcadores de Tumor/biosíntesis , Citodiagnóstico , Femenino , Humanos , Pulmón/patología , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Persona de Mediana Edad
6.
Nihon Kyobu Shikkan Gakkai Zasshi ; 30(9): 1743-8, 1992 Sep.
Artículo en Japonés | MEDLINE | ID: mdl-1447852

RESUMEN

Bucillamine [N-(2-mercapto-2-methylpropionyl)-L-cysteine] is an anti-rheumatic drug which was developed in Japan. Interstitial pneumonia induced by bucillamine has been reported in two patients with rheumatoid arthritis. In this report, we describe another patient who developed bucillamine-induced interstitial pneumonia. In August 1990, a 53-year-old man was admitted because of fever, dry cough and dyspnea on exertion (DOE). Five months previously, he had noted polyarthritis, and treatment with bucillamine was started in May 1990. His polyarthritis improved about 2.5 months after starting bucillamine, but he developed fever, dry cough, and DOE in August 1990. Chest X-ray on admission showed diffuse acinar and interstitial shadows predominantly in the bilateral upper lung fields. Pulmonary function tests revealed decreased vital capacity and diffusing capacity. Arterial blood gas (ABG) analysis revealed moderate hypoxemia with PaO2 67 Torr. After stopping bucillamine, the fever, dry cough, and DOE improved gradually, and the abnormal shadows on chest X-ray and ABG analysis showed moderate improvements. Bronchoalveolar lavage studies showed that total cell counts and proportion of lymphocytes were increased, and CD4+/CD8+ ratio of T cell subsets was decreased to 0.56. Transbronchial lung biopsy specimen revealed lymphocytic alveolitis and mild interstitial thickening. Lymphocyte stimulation test to bucillamine was negative, but patch test with bucillamine was positive. From the patient's clinical course, laboratory data, and pathologic findings, we concluded that this is a case of bucillamine-induced interstitial pneumonia. After treatment with corticosteroid, his chest X-ray and pulmonary function test showed marked improvements.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Cisteína/análogos & derivados , Fibrosis Pulmonar/inducido químicamente , Artritis/tratamiento farmacológico , Cisteína/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Pruebas del Parche
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...